Accelerated induction regimens of TNFalpha inhibitors in patients with inflammatory bowel disease: a scoping review protocol
Loading...
Date
2018-01-19
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Introduction Tumour necrosis factor (TNF)-alpha
inhibitors are commonly used to treat inflammatory bowel
disease (IBD). In patients with IBD who are unresponsive
to their first induction dose, the implementation of an
‘accelerated’ induction dose schedule (doses more
frequent than recommended in product monographs) is
becoming increasingly common. It is unclear whether
this practice results in favourable patient outcomes,
such as avoidance of surgery and disease remission.
As such, there is a need to identify and map the current
evidence base on accelerated induction schedules of these
medications in the treatment of IBD.
Methods and analysis A scoping review will be
employed to systematically identify and characterise the
nature of scientific literature on accelerated induction
regimens of TNF-alpha inhibitors. MEDLINE, Embase,
International Pharmaceutical Abstracts and grey literature
will be searched to identify relevant studies. The titles/
abstracts of all records and full text of potentially relevant
articles will be independently screened for inclusion by two
reviewers. Data will be abstracted from included studies
by one reviewer and verified for accuracy by another. The
findings will be synthesised descriptively.
Ethics and dissemination We intend to report the
findings of this scoping review in a peer-reviewed journal
and a scientific conference.
Trial registration This research was registered
prospectively with the Open Science Framework (https://
osf. io/ z7n2d/).
Description
Keywords
Citation
Johnston A, et al. BMJ Open 2018;8:e019909. doi:10.1136/bmjopen-2017-019909